Oncology & Cancer

ASCO: Pembrolizumab superior for initial Tx of advanced NSCLC

(HealthDay)—For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced or metastatic non-small-cell lung cancer (NSCLC), pembrolizumab is associated with better overall survival than chemotherapy, regardless ...

page 1 from 3